Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Gyre Therapeutics (GYRE) Receivables - Net (2016 - 2026)

Gyre Therapeutics has reported Receivables - Net over the past 16 years, most recently at $31.1 million for Q4 2025.

  • Quarterly Receivables - Net rose 58.65% to $31.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.1 million through Dec 2025, up 58.65% year-over-year, with the annual reading at $31.1 million for FY2025, 58.65% up from the prior year.
  • Receivables - Net was $31.1 million for Q4 2025 at Gyre Therapeutics, up from $26.6 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $31.1 million in Q4 2025 and troughed at $564000.0 in Q1 2022.
  • The 5-year median for Receivables - Net is $15.2 million (2023), against an average of $12.9 million.
  • Year-over-year, Receivables - Net plummeted 45.13% in 2021 and then surged 842.57% in 2022.
  • A 5-year view of Receivables - Net shows it stood at $1.8 million in 2021, then surged by 842.57% to $17.1 million in 2022, then fell by 11.27% to $15.2 million in 2023, then grew by 28.84% to $19.6 million in 2024, then soared by 58.65% to $31.1 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Receivables - Net are $31.1 million (Q4 2025), $26.6 million (Q3 2025), and $24.9 million (Q2 2025).